多巴胺能激动剂的透皮给药法

左旋多巴是目前治疗帕金森病（PD）最有效的药物，但长期使用会引起药物的疗效下降并出现相应的并发症。随着持续性多巴胺（DA）能刺激可以避免不随意运动等并发症的发生这一观念的出现，人们开始寻找能够给予DA受体持续性、生理性刺激作用的给药方法。透皮制剂不仅能够持续性给药，更是一种非创伤性的相对简单的给药方法。过去一些透皮给药治疗PD的试验并不成功，如吡贝地尔和那高利特等，但对于罗替戈汀进行的随机双盲对照试验则取得了阳性结果。DA能激动剂的透皮给药法完成了抗PD药物的第3阶段的发展，并且在不久的将来会被逐渐完善。

Transdermal Delivery of Dopaminergic Agents

Levodopa is the most effective drug for treating the symptoms of Parkinson＇ s disease（PD）. But its long-term use is associated with loss of efficacy and the onset of motor complications. With the producing of the concept that continuous dopaminergic stimulation would avoid the onset of complications, such as involuntary movements, treatment approaches that might provide more constancy, and therefore physiological and dopamine receptor stimulation have been sought. Transdermal drug delivery is a treatment approach that is not only capable of providing a constant rate of drug delivery, but is also non-invasive and relatively simple to use. Previous trials of transdermal drug delivery in PD, with piribedil and naxagolide for example, have been unsuccessful. In contrast, some randomized, double-blind, placebo-controlled trials conducted with rotigotine showed the positive and encouraging results. Transdermal delivery of dopaminergic agents has completed Phase Ⅲ development, and regulatory approval is expected in the near future.